GLP-1 Drugs Linked to GI Effects, Uncertain Signals - Summary - MDSpire
From the Journals

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.

Share

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were analyzed across 60 meta-analyses involving 1,751 trials with 3.6 million participants, predominantly those with type 2 diabetes or obesity. Strong associations were noted for gastrointestinal issues such as nausea, vomiting, and diarrhea, with evidence quality rated from high to moderate. Serological links to lower risks of serious infections and respiratory diseases were indicated, though many findings lacked strong corroborative evidence. Lead author Kaijie Yang, MD, underscores the insufficiency of high-certainty conclusions from the current body of research.

Original Source(s)

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Why Extraction Still Matters in Food Analysis

Ahead of ExTech 2026, Hans-Gerd Janssen weighs in on the challenges and evolution of sample preparation

Diabetes Self-Care Declines During Breast Cancer Treatment

Patients experience reduced monitoring, emotional distress, and gaps in coordinated care during adjuvant therapy

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.